Microvolt T-wave alternans identifies patients with ischemic cardiomyopathy who benefit from implantable cardioverter-defibrillator therapy.

OBJECTIVES This study sought to assess whether implantable cardioverter-defibrillators (ICDs) have different mortality benefits among patients with ischemic cardiomyopathy who screen negative and non-negative (positive and indeterminate) for microvolt T-wave alternans (MTWA). BACKGROUND Microvolt T-wave alternans has been proposed as an effective tool for risk stratification. However, no studies have examined whether ICD benefits differ by MTWA group. METHODS We developed a prospective cohort of 768 patients with ischemic cardiomyopathy (left ventricular ejection fraction < or =35%) and no prior sustained ventricular arrhythmia, of which 392 (51%) received ICDs. The mean follow-up time was 27 +/- 12 months. Propensity scores for ICD implantation based on the variables most likely to influence defibrillator implantation were developed for each MTWA cohort. Multivariable Cox analyses that controlled for propensity score, demographics, and clinical variables evaluated the degree to which ICDs decreased mortality risk for each MTWA group. RESULTS We identified 514 (67%) patients with a non-negative MTWA test result. After multivariable adjustment, ICDs were associated with lower all-cause mortality in MTWA-non-negative patients (hazard ratio [HR] 0.45, 95% confidence interval [CI] 0.27 to 0.76, p = 0.003) but not in MTWA-negative patients (HR 0.85, 95% CI 0.33 to 2.20, p = 0.73) (for interaction, p = 0.04), with the mortality benefit in MTWA-non-negative patients largely mediated through arrhythmic mortality reduction (HR 0.30, 95% CI 0.13 to 0.68, p = 0.004). The number needed to treat with an ICD for 2 years to save 1 life was 9 among MTWA-non-negative patients and 76 among MTWA-negative patients. CONCLUSIONS In patients with ischemic cardiomyopathy and no prior history of ventricular arrhythmia, mortality reduction with ICD implantation differs by MTWA status, with implications for risk stratification and health policy.

[1]  M. Stampfer,et al.  Test of the National Death Index and Equifax Nationwide Death Search. , 1994, American journal of epidemiology.

[2]  R. Califf,et al.  Clinical and Economic Implications of the Multicenter Automatic Defibrillator Implantation Trial-II , 2005, Annals of Internal Medicine.

[3]  P. Chan,et al.  Microvolt T-wave alternans: where do we go from here? , 2006, Journal of the American College of Cardiology.

[4]  Donald Rubin,et al.  Estimating Causal Effects from Large Data Sets Using Propensity Scores , 1997, Annals of Internal Medicine.

[5]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[6]  S. Hohnloser,et al.  T-wave alternans negative coronary patients with low ejection and benefit from defibrillator implantation , 2003, The Lancet.

[7]  M. Mcclellan,et al.  Medicare coverage of ICDs. , 2005, The New England journal of medicine.

[8]  J. Windle,et al.  Quality‐of‐Life Six Months After CABG Surgery in Patients Randomized to ICD Versus No ICD Therapy: Findings from the CABG Patch Trial , 1999, Pacing and clinical electrophysiology : PACE.

[9]  J Thomas Bigger,et al.  Microvolt T-Wave Alternans Distinguishes Between Patients Likely and Patients Not Likely to Benefit From Implanted Cardiac Defibrillator Therapy: A Solution to the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II Conundrum , 2004, Circulation.

[10]  L E Hinkle,et al.  Clinical Classification of Cardiac Deaths , 1982, Circulation.

[11]  A. Moss,et al.  Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II). , 2004, Journal of the American College of Cardiology.

[12]  Brahmajee K Nallamothu,et al.  Prognostic utility of microvolt T-wave alternans in risk stratification of patients with ischemic cardiomyopathy. , 2006, Journal of the American College of Cardiology.

[13]  P. Chan,et al.  Cost-effectiveness of a microvolt T-wave alternans screening strategy for implantable cardioverter-defibrillator placement in the MADIT-II-eligible population. , 2006, Journal of the American College of Cardiology.

[14]  V. Fuster,et al.  Primary prophylaxis with the implantable cardioverter-defibrillator: The need for improved risk stratification , 2005 .

[15]  Judy Powell,et al.  Quality of Life in the Antiarrhythmics Versus Implantable Defibrillators Trial: Impact of Therapy and Influence of Adverse Symptoms and Defibrillator Shocks , 2002, Circulation.

[16]  J. A. Gomes,et al.  Microvolt T-wave alternans for the risk stratification of ventricular tachyarrhythmic events: a meta-analysis. , 2005, Journal of the American College of Cardiology.

[17]  Wojciech Zareba,et al.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. , 2002, The New England journal of medicine.

[18]  A. Buxton.  Risk stratification for sudden death: do we need anything more than ejection fraction? , 2003, Cardiac electrophysiology review.

[19]  Richard J Cohen,et al.  Interpretation and Classification of Microvolt T Wave Alternans Tests , 2002, Journal of cardiovascular electrophysiology.

[20]  R. Hayward,et al.  Mortality reduction by implantable cardioverter-defibrillators in high-risk patients with heart failure, ischemic heart disease, and new-onset ventricular arrhythmia: an effectiveness study. , 2005, Journal of the American College of Cardiology.

[21]  M. Rosenqvist,et al.  Adverse events with transvenous implantable cardioverter-defibrillators: a prospective multicenter study. European 7219 Jewel ICD investigators. , 1998, Circulation.

[22]  D. Rubin,et al.  The central role of the propensity score in observational studies for causal effects , 1983 .

[23]  J. A. Gomes,et al.  CorrespondenceLetter to the EditorReply , 2006 .